Skip to main content

Table 1 Characteristics of the Norwegian and Swedish cohorts

From: Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

     p value
  Controls MCI AD Controls–MCI Controls–AD MCI–AD
Norwegian cohort n = 50 n = 21 n = 29    
Gender       
 Women 25 12 13    
 Men 25 9 16    
Age 66 (50–86) 67 (55–75) 68 (56–75)    
MMSE 29 (29–30) 27 (26–29) 20 (17–24) * * *
CSF Aβ42 (pg/ml) 1010 (880–1188) 494 (356–531) 500 (386–553) * * 0.43
CSF T-tau (pg/ml) 307 (201–391) 628 (497–927) 772 (647–1143) * * 0.06
CSF P-tau (pg/ml) 51 (38–61) 75 (62–111) 72 (67–91) * * 1.00
ApoE genotype       
 E2/E3 8 1    
 E2/E4   1    
 E3/E3 35 5 5    
 E3/E4 6 8 12    
 E4/E4 8 10    
 Not known 1      
CSF sTREM2 (ng/ml) 4.4 (3.0–5.7) 4.1 (2.4–5.9) 4.8 (3.5–7.1) 0.42 0.17 0.11
Swedish cohort n = 25   n = 25    
Gender       
 Women 17   18    
 Men 8   7    
Age 62 (43–80)   79 (61–86)    
MMSE 29 (28–30)   18 (13–22)   *  
CSF Aβ42 (pg/ml) 520 (469–597)   340 (265–430)   *  
CSF T-tau (pg/ml) 380 (233–480)   670 (490–895)   *  
CSF P-tau (pg/ml) 44 (36–61)   80 (69–96)   *  
ApoE genotype       
 E2/E3 5   1    
 E2/E4 1   1    
 E3/E3 14   4    
 E3/E4 4   15    
 E4/E4 1   4    
CSF sTREM2 (ng/ml) 3.2 (2.8–5.0)   3.8 (2.6–5.6)   0.76  
  1. Descriptive statistics of gender, age, MMSE, ApoE genotype and CSF biomarker data of AD, MCI and control patients of the two cohorts
  2. Data are presented as median (interquartile range), except age which is presented as median (minimum–maximum). Two-tailed p values obtained by Mann–Whitney U test for group comparison
  3. *p < 0.001
  4. Aβ42 amyloid beta 1–42, AD Alzheimer’s disease, ApoE apolipoprotein E, CSF cerebrospinal fluid, MCI mild cognitive impairment, MMSE Mini-Mental State Examination, P-tau phosphorylated Tau, sTREM2 soluble triggering receptor expressed on myeloid cells 2, T-tau total Tau